From Satiety to Reward Reshaping: Central Mechanisms of GLP-1 Receptor Agonists and Therapeutic Implications for Reward-related Disorders.
Abstract
The classical theory of glucagon-like peptide-1 receptor agonists (GLP-1RAs) emphasizes peripheral metabolic regulation and satiety mediated by hypothalamic-brainstem homeostatic pathways. However, numerous clinical studies have shown that GLP-1RAs significantly suppress patients' food cravings and simultaneously reduce cravings for non-food reinforcers such as alcohol and nicotine, suggesting that the effects of GLP-1RAs extend far beyond the regulation of energy balance. GLP-1 receptors are expressed in the ventral tegmental area, the nucleus accumbens, and the central amygdala; their activation exhibits phase-specific effects: during the reward anticipation phase, they reduce dopamine signaling in the nucleus accumbens, whereas during the intake phase, they enhance this signaling. GLP-1RAs can modulate the mesolimbic dopamine system, likely through a combination of direct central actions and indirect peripheral- to-central signaling pathways, dynamically modulating reward processing rather than simply inhibiting it. Given that the mesolimbic dopamine system serves as a common neural substrate for both food and drug addiction, the observed modulatory effects of GLP-1RAs on various reinforcers suggest preliminary potential for expanded application in the treatment of binge eating disorder and substance use disorders, although clinical evidence remains limited for most non-food indications. Future research should elucidate the central penetration characteristics of different agonists, their cell-type-specific mechanisms of action, and the persistence of their neuromodulatory effects to advance the development of precision therapeutic strategies targeting specific reward circuits.